Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology（2023）
摘要
Cancer Research UK and Janssen.
更多查看译文
关键词
chronic lymphocytic leukaemia,untreated chronic lymphocytic leukaemia,rituximab,fludarabine,cyclophosphamide,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要